



(51) International Patent Classification:

C07D 498/14 (2006.01) C07D 471/22 (2006.01)
C07D 471/04 (2006.01) C07D 487/04 (2006.01)
C07D 471/14 (2006.01)

(21) International Application Number:

PCT/US2013/076367

(22) International Filing Date:

19 December 2013 (19.12.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/745,375 21 December 2012 (21.12.2012) US
61/788,397 15 March 2013 (15.03.2013) US
61/845,803 12 July 2013 (12.07.2013) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors: JIN, Haolun; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, CA 94404 (US). LAZER-
WITH, Scott, E.; c/o Gilead Sciences, Inc., 333 Lakeside
Drive, Foster City, CA 94404 (US). MARTIN, Teresa,
Alejandra, Trejo; c/o Gilead Sciences, Inc., 333 Lakeside
Drive, Foster City, CA 94404 (US). BACON, Elizabeth,
M.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster
City, CA 94404 (US). COTTELL, Jeromy, J.; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404
(US). CAI, Zhenhong, R.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, CA 94404 (US). PYUN, Hy-
ung-Jung; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, CA 94404 (US). MORGANELLI, Philip,
Anthony; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, CA 94404 (US). JI, Mingzhe; c/o Gilead Sci-
ences, Inc., 333 Lakeside Drive, Foster City, CA 94404

(US). TAYLOR, James, G.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, CA 94404 (US). CHEN, Xi-
aowu; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, CA 94404 (US). MISH, Michael, R.; c/o
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA
94404 (US). DESAI, Manoj, C.; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, CA 94404 (US).

(74) Agents: WAGNER, Emily, W. et al.; Cooley LLP, 1299
Pennsylvania Avenue, NW, Suite 700, Washington, DC
20004 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE



(57) Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R₁, X, W, Y₁, Y₂, Z₁ and Z₄ are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.